Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. 2007

Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
Department of Oral and Maxillofacial Surgery, School of Medicine, Wakayama Medical University, Japan.

To investigate the mechanism of the resistance to cisplatin (CDDP), we established the CDDP-resistant cell line, KB-R, from CDDP-sensitive oral carcinoma cell line, KB. The 3-(3, 4-dimethyl-thiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) assay indicated that KB-R is 5.5-fold more resistant to CDDP than KB. Microarray analysis indicated that the expression levels of 1,718 genes were elevated at least five-fold or more in KB-R, compared with KB. The expression status of ATP binding cassette (ABC) transporter genes, which belong to multi-drug resistance genes, was confirmed by semiquantitative reverse transcriptase-polymerase chain reaction and real-time PCR. MRP1 and MRP2 were up-regulated, whereas MDR1 was down-regulated. Pathway and ontology analysis using the Ingenuity Pathway Analysis tool indicated three highly significant genetic networks including 105 of the 1,718 overexpressed genes and one network including 35 'cell-to-cell signaling and interaction' related genes. Our results suggested that these cell lines, KB and KB-R, may be useful for searching the candidate genes responsible for CDDP-resistance and for further study to understand the mechanism of CDDP-resistance.

UI MeSH Term Description Entries
D007624 KB Cells This line KB is now known to be a subline of the ubiquitous KERATIN-forming tumor cell line HeLa. It was originally thought to be derived from an epidermal carcinoma of the mouth, but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, to have been established via contamination by HELA CELLS. The cells are positive for keratin by immunoperoxidase staining. KB cells have been reported to contain human papillomavirus18 (HPV-18) sequences. HeLa-KB Cells,Cell, HeLa-KB,Cell, KB,Cells, HeLa-KB,Cells, KB,HeLa KB Cells,HeLa-KB Cell,KB Cell
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D019450 Genes, MDR Genes for MEMBRANE TRANSPORT PROTEINS that confer resistance to toxic compounds. Several superfamilies of these multidrug export proteins are known and found in both prokaryotes and eukaryotes. MDR Genes,Multidrug Resistance Gene,Multidrug Efflux Pump Genes,Gene, MDR,Gene, Multidrug Resistance,Genes, Multidrug Resistance,MDR Gene,Multidrug Resistance Genes,Resistance Gene, Multidrug,Resistance Genes, Multidrug
D020133 Reverse Transcriptase Polymerase Chain Reaction A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols. Polymerase Chain Reaction, Reverse Transcriptase,Reverse Transcriptase PCR,PCR, Reverse Transcriptase,Transcriptase PCR, Reverse
D020411 Oligonucleotide Array Sequence Analysis Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING. DNA Microarrays,Gene Expression Microarray Analysis,Oligonucleotide Arrays,cDNA Microarrays,DNA Arrays,DNA Chips,DNA Microchips,Gene Chips,Oligodeoxyribonucleotide Array Sequence Analysis,Oligonucleotide Microarrays,Sequence Analysis, Oligonucleotide Array,cDNA Arrays,Array, DNA,Array, Oligonucleotide,Array, cDNA,Arrays, DNA,Arrays, Oligonucleotide,Arrays, cDNA,Chip, DNA,Chip, Gene,Chips, DNA,Chips, Gene,DNA Array,DNA Chip,DNA Microarray,DNA Microchip,Gene Chip,Microarray, DNA,Microarray, Oligonucleotide,Microarray, cDNA,Microarrays, DNA,Microarrays, Oligonucleotide,Microarrays, cDNA,Microchip, DNA,Microchips, DNA,Oligonucleotide Array,Oligonucleotide Microarray,cDNA Array,cDNA Microarray

Related Publications

Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
January 1993, Acta oto-laryngologica. Supplementum,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
November 2005, Oncology reports,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
April 2005, Oncology reports,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
January 1998, Chemotherapy,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
January 1999, Anticancer research,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
September 2014, Oncology reports,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
June 2002, Virchows Archiv : an international journal of pathology,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
January 1997, Cancer chemotherapy and pharmacology,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
January 1990, Acta oto-laryngologica,
Kenji Negoro, and Yukio Yamano, and Kazuaki Fushimi, and Kengo Saito, and Ken Nakatani, and Masashi Shiiba, and Hidetaka Yokoe, and Hiroki Bukawa, and Katsuhiro Uzawa, and Takeshi Wada, and Hideki Tanzawa, and Shigeyuki Fujita
April 2015, Pathology, research and practice,
Copied contents to your clipboard!